Clinical trials: Alteplase
COVID
Nebulised Rt-PA for ARDS Due to COVID-19
Some patients infected with COVID-19 develop a severe form of a lung disease called acute respiratory distress syndrome (ARDS). In these patients, the lungs become severely inflamed because of the virus.
- Trial name
- PACA (NCT04356833)
- Testing
- Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University College, London
Short Bowel Syndrome
rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
The primary research question is, in patients with short bowel syndrome requiring central venous access device (CVAD) for long-term total parenteral nutrition, is once weekly recombinant tissue plasminogen activator (rtPA) lock…
- Trial name
- NCT02355743
- Testing
- rtPA lock therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Lynn Malec
Intracranial Embolism, Thrombosis
Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion
The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz TCCS in stroke patients…
- Trial name
- NCT00336596
- Testing
- transcranial ultrasound in patients treated with iv t-PA
- Where
- 6 sites in Switzerland
- Volunteers
- 400 people
- Sponsor
- University of Zurich
Dysfunctional Central Venous Access Devices (CVADS)
Cathflo Activase Pediatric Study
This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at ~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple…
- Trial name
- NCT00307580
- Testing
- Cathflo Activase (Alteplase)
- Volunteers
- 300 people
- Sponsor
- Genentech, Inc.
Chronic Renal Insufficiency
Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol
Central venous catheters (CVCs) are used for vascular access by approximately 56% of our 380 hemodialysis (HD) patients at the Capital Health Renal Program.
- Trial name
- NCT02474810
- Testing
- Alteplase
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Nova Scotia Health Authority
Stroke
Increasing Stroke Treatment Through Interventional Change Tactics Study
The purpose of this study is to evaluate a standardized, system-based, barrier assessment and interactive educational intervention to increase appropriate t-PA use for stroke.
- Trial name
- INSTINCT (NCT00349479)
- Testing
- Barrier assessment / interactive educational intervention
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Michigan
Empyema
Empyema Treated With tPA & DNAse
The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA. The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse.
- Trial name
- NCT01862458
- Testing
- tPA alone, tPA plus dornase
- Where
- United States
- Sponsor
- Children's Mercy Hospital Kansas City
Deep Vein Thrombosis, Post-Thrombotic Syndrome
Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
The purpose of this study is to determine if the use of adjunctive catheter-directed thrombolysis (CDT), which includes the intrathrombus administration of rt-PA (Activase/Alteplase), can prevent post-thrombotic syndrome (PTS) in…
- Conditions
- Deep Vein Thrombosis, Post-Thrombotic Syndrome, Venous Thrombosis
- Trial name
- PHLO (NCT02767232)
- Testing
- Recombinant tissue plasminogen activator (rt-PA), Standard Anticoagulation Therapy
- Sponsor
- University of Colorado, Denver
Thrombosis
Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.
- Trial name
- NCT00265005
- Testing
- alteplase
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Louisville
Embolism, Thrombophlebitis
Treatment for Blood Clots in the Veins of the Legs
Acute deep venous thrombosis (ADVT) of the lower extremity is a common disorder. Traditional treatment with anticoagulation therapy is effective in reducing the associated risk of pulmonary embolism, but is ineffective in…
- Trial name
- NCT00001713
- Testing
- Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ischemic Stroke, Thrombolytic (t-PA) Treatment
Long-Term Survival After Ischaemic Stroke: Ebrictus Study
A number of large trials have confirmed the benefits of thrombolysis in acute stroke, but there are gender differences. The authors sought to examine the relationship between sex and outcome after thrombolysis.
- Conditions
- Ischemic Stroke, Thrombolytic (t-PA) Treatment, Gender Bias, Long Term Adverse Effects
- Trial name
- EBRICTUS (NCT03247036)
- Testing
- IV thrombolytic (t-PA) treatment vs not
- Where
- Spain
- Volunteers
- 21,000 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Plastic Bronchitis, Protein-Losing Enteropathies
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic bronchitis (PB) is a rare, most often pediatric disease characterized by the formation of obstructive airway casts primarily composed of fibrin.
- Conditions
- Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
- Trial name
- PLATyPuS (NCT02315898)
- Testing
- Treatment-inhaled tPA
- Where
- 6 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Deep Vein Thrombosis, Venous Thrombosis
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic…
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism
- Trial name
- ATTRACT (NCT00790335)
- Testing
- Recombinant tissue plasminogen activator (rt-PA)
- Where
- 56 sites in United States
- Volunteers
- 692 people
- Sponsor
- Washington University School of Medicine
Periodontal Diseases, Periodontal Attachment Loss
Low-level Laser Therapy as an Adjunct to Non-surgical Periodontal Treatment
The present study aimed to investigate the effects of low-level laser therapy (LLLT) as an adjunct to non-surgical periodontal treatment (NSPT) on the plasminogen-activating system in Stage 3-4, Grade C periodontitis patients.
- Conditions
- Periodontal Diseases, Periodontal Attachment Loss, Periodontal Disease, AVDC Stage 3, Periodontal Inflammation
- Trial name
- NCT05233501
- Testing
- low level laser therapy, non-surgical periodontal treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Beykent
Congenital Heart Disease, Fibrinolysis
Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis
Lysine analogs, like tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), are antifibrinolytic agents routinely administered in children undergoing different surgeries associated with a high bleeding risk (e.g.
- Conditions
- Congenital Heart Disease, Fibrinolysis, Rotational Thromboelastometry
- Trial name
- NCT02352675
- Testing
- Intraoperative Blood Sample
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boston Children's Hospital
Pleural Empyema
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Bacterial pneumonia can be complicated by the development of excess fluid and pus (pleural empyema) around the lungs in children. The incidence of pleural empyema in children has increased significantly in the last 10 years.
- Trial name
- NCT01717742
- Testing
- TPA (Tissue Plasminogen Activator), DNase
- Where
- 6 sites in Canada
- Volunteers
- 97 people
- Sponsor
- The Hospital for Sick Children
Cardiovascular Diseases, Heart Diseases
Genetic Architecture of Plasma T-PA and PAI-1
To determine the effects of six genes on thrombotic risk factors known to be associated with the development of heart disease.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Thrombosis, Atherosclerosis
- Trial name
- NCT00007410
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing…
- Trial name
- TOPCAT (NCT03672006)
- Testing
- alteplase (recombinant t-PA), Heparin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Abdominal Abscess, Tissue Plasminogen Activator
Treatment of Abdominal Abscesses With or Without Fibrinolysis
The objective of this study is to evaluate the utility of fibrinolysis when draining an abdominal abscess as defined by length of stay after drainage.
- Trial name
- NCT01597336
- Testing
- Tissue plasminogen activator abscess flush, Saline flush of abscess
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Children's Mercy Hospital Kansas City
Diabetic Macular Edema
Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).
- Trial name
- NCT01141881
- Testing
- Tissue Plasminogen Activator,bevacizumab ,follow up
- Where
- Iran
- Sponsor
- Mashhad University of Medical Sciences